Breast-cancer drug creates cost dilemma
Article Abstract:
A designer drug has been approved by Health Canada for use in genetic therapy in the treatment of breast cancer. The drug called trastuzumab, marketed under the brand name Herceptin, was developed by San Francisco, CA-based biotechnology firm Genentech Inc which has since then been acquired by Roche Holding AG. The drug is only effective in breast cancer caused by a gene defect that results in overproduction of a protein called HER2, which in turn leads to runaway growth of cancer cells and tumors.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Scientists hope to trigger temporary 'vasectomy'
Article Abstract:
University of Leicester researchers have made a breakthrough that may lead to the development of a male contraceptive pill. The British scientists have been using genetic engineering techniques on mice to develop the oral contraceptive.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: DWL secures financing deal. Venture capitalists profit in tech sector. Classwave Wireless wins venture capital deal
- Abstracts: B.C.'s forestry dispute heats up. Interfor lends ear to groups' views
- Abstracts: CN estimates strike cost as much as $40-million. Scotiabank big lender to Warnaco. Harry Potter and the e-commerce revolution
- Abstracts: Bank error in your favour: Collect $17-million. Scotiabank posts record profit for quarter, year. RBC posts record year-end profit
- Abstracts: Cinar denies request for special meeting. Economy needs help to adapt: Dodge